- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07881887
A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
A Phase 1, Randomized, Participant- and Investigator-Blinded, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Dose Regimens of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration.
Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical Research Unit (CRU), each stay lasting between approximately 8 and 10 nights.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- Telefonnummer: 1-317-615-4559
- E-post: LillyTrials@Lilly.com
Studer Kontakt Backup
- Navn: Physicians interested in becoming principal investigators please contact
- E-post: clinical_inquiry_hub@lilly.com
Studiesteder
-
-
Arkansas
-
Rogers, Arkansas, Forente stater, 72758
- Har ikke rekruttert ennå
- Woodland Research Northwest, LLC
-
Ta kontakt med:
- Telefonnummer: 479-927-3000
-
Hovedetterforsker:
- Timothy Cook
-
-
California
-
Anaheim, California, Forente stater, 92801
- Rekruttering
- CenExel ACT
-
Hovedetterforsker:
- Amina Haggag
-
Los Alamitos, California, Forente stater, 90720
- Rekruttering
- Collaborative Neuroscience Network - CNS
-
Hovedetterforsker:
- Steven Reynolds
-
Walnut Creek, California, Forente stater, 94598
- Rekruttering
- Diablo Clinical Research, Inc.
-
Hovedetterforsker:
- Bonnie Kimmel
-
-
Florida
-
Daytona Beach, Florida, Forente stater, 32117
- Rekruttering
- Fortrea Clinical Research Unit
-
Ta kontakt med:
- Telefonnummer: 866-429-3700
-
Hovedetterforsker:
- Chiamaka Iheme
-
Miami, Florida, Forente stater, 33417
- Har ikke rekruttert ennå
- Advanced Pharma CR, LLC
-
Hovedetterforsker:
- Simon Abelson
-
Winter Park, Florida, Forente stater, 32789
- Rekruttering
- Clinical Site Partners, LLC DBA CSP Orlando
-
Hovedetterforsker:
- ROBERT MEYER
-
-
Georgia
-
Columbus, Georgia, Forente stater, 31904
- Rekruttering
- Centricity Research
-
Hovedetterforsker:
- Joseph Surber
-
Ta kontakt med:
- Telefonnummer: 706-321-0495
-
Decatur, Georgia, Forente stater, 30030
- Rekruttering
- CenExel iResearch, LLC
-
Hovedetterforsker:
- Kimball Johnson
-
-
Missouri
-
Springfield, Missouri, Forente stater, 65802
- Rekruttering
- QPS
-
Hovedetterforsker:
- Leea Reed
-
Ta kontakt med:
- Telefonnummer: 417-893-6161
-
-
New Jersey
-
Marlton, New Jersey, Forente stater, 08053
- Rekruttering
- CenExel-HRI
-
Hovedetterforsker:
- Kyle Coupe
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43212
- Rekruttering
- Ohio Clinical Trials
-
Hovedetterforsker:
- Angela Eakin
-
-
Texas
-
Dallas, Texas, Forente stater, 75247
- Rekruttering
- Fortrea Clinical Research Unit
-
Hovedetterforsker:
- Archie Bowie
-
San Antonio, Texas, Forente stater, 78217
- Rekruttering
- Worldwide Clinical Trials, Inc.
-
Hovedetterforsker:
- Alan Hand
-
-
-
-
-
Singapore, Singapore, 138623
- Har ikke rekruttert ennå
- Lilly Centre for Clinical Pharmacology
-
Ta kontakt med:
- Telefonnummer: 64139811
-
Hovedetterforsker:
- Jennifer Boon Wee
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Participants must be 21 in Singapore.
- Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent (%) body weight change.
Part A, B, D, and E
-
Have a body mass index (BMI) of greater than or equal to 30 kilograms per square meter (kg/m²) or 27 to less than 30 kg/m² and previously diagnosed with at least one of the following weight-related comorbidities:
- hypertension
- dyslipidemia
- obstructive sleep apnea, or
- prediabetes.
Part C
- Have a BMI ≥25.0 kg/m²
- Have a diagnosis of Type 2 Diabetes (T2D) for at least 6 months.
- T2D controlled with diet and exercise alone or are on a stable dose of metformin alone, or in combination with a sodium-glucose co-transporter-2 inhibitor (SGLT-2i), for at least 3 months.
- Have a hemoglobin (HbA1c) value of ≥6.5 % and ≤10.0%.
Part D
- To qualify as Chinese for this study, the participant must be at a minimum third-generation Chinese, defined as having all 4 of the participants' biological grandparents being of exclusive Chinese descent and born in China.
Part E
- To qualify as Japanese for this study, the participant must be at a minimum third-generation Japanese, defined as having all 4 of the participants' biological grandparents being of exclusive Japanese descent and born in Japan.
Exclusion Criteria:
- Have a significant history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine (except for T2D in Part C), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Part A: LY4167586
LY4167586 administered subcutaneously (SC) |
administered SC |
|
Eksperimentell: Part B LY4167586
LY4167586 administered SC |
administered SC |
|
Eksperimentell: Part C LY4167586
LY4167586 administered SC |
administered SC |
|
Eksperimentell: Part D LY4167586
LY4167586 administered SC |
administered SC |
|
Eksperimentell: Part E LY4167586
LY4167586 administered SC |
administered SC |
|
Placebo komparator: Placebo (Part A-E)
Placebo administered SC |
administered SC |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Tidsramme: Baseline through Study Completion (Estimated as Week 89)
|
Baseline through Study Completion (Estimated as Week 89)
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY4167586
Tidsramme: Baseline up to Week 89
|
Baseline up to Week 89
|
|
PK: Area Under the Concentration Time Curve (AUC) of LY4167586
Tidsramme: Baseline up to Week 89
|
Baseline up to Week 89
|
|
Body Weight Observed Value
Tidsramme: Baseline up to Week 89
|
Baseline up to Week 89
|
|
Change from Baseline in Body Weight
Tidsramme: Baseline up to Week 89
|
Baseline up to Week 89
|
|
Percent Change from Baseline in Body Weight
Tidsramme: Baseline up to Week 89
|
Baseline up to Week 89
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 27671
- J6L-MC-YIAB (Annen identifikator: Eli Lilly and Company)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .